Sorafenib in advanced hepatocellular carcinoma–we have won a battle not the war
PR Galle - Journal of hepatology, 2008 - Elsevier
Sorafenib in advanced hepatocellular carcinoma. Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C …
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C …
Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC
TF Greten, MP Manns, N Malek - Zeitschrift fur Gastroenterologie, 2009 - europepmc.org
Sorafenib increases overall survival in patients with advanced HCC by almost three months.
However, despite these advances in the treatment of patients with HCC, average overall …
However, despite these advances in the treatment of patients with HCC, average overall …
Molecular targeted therapy for hepatocellular carcinoma: where are we now?
M Kudo - Liver cancer, 2015 - karger.com
Seven years have passed since sorafenib was approved as a systemic chemotherapeutic
agent that improves survival in patients with advanced hepatocellular carcinoma (HCC) …
agent that improves survival in patients with advanced hepatocellular carcinoma (HCC) …
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
J Arrondeau, O Mir, P Boudou-Rouquette… - Investigational new …, 2012 - Springer
Background Intra-patient variability in sorafenib pharmacokinetics has been poorly
investigated to date. We hypothesized that sorafenib clearance could decrease over time, as …
investigated to date. We hypothesized that sorafenib clearance could decrease over time, as …
Hepatocellular carcinoma: the place of new medical therapies
M Peck-Radosavljevic - Therapeutic Advances in …, 2010 - journals.sagepub.com
Medical therapies have entered center stage in the treatment of hepatocellular carcinoma
(HCC) little more than a year after the positive results of a large phase III trial of sorafenib …
(HCC) little more than a year after the positive results of a large phase III trial of sorafenib …
Effects of sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma
EA Kuczynski, CR Lee, S Man, E Chen, RS Kerbel - Cancer research, 2015 - AACR
Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC)
treatment with the tyrosine kinase inhibitor (TKI) sorafenib. Recent findings suggest that …
treatment with the tyrosine kinase inhibitor (TKI) sorafenib. Recent findings suggest that …
Sorafenib: experience and better management of side effects improve overall survival in hepatocellular carcinoma patients: a real-life retrospective analysis
JL Raoul, X Adhoute, G Penaranda, H Perrier… - Liver cancer, 2019 - karger.com
Background: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma
(HCC). The management of its side effects is improving. This study aimed to assess, in real …
(HCC). The management of its side effects is improving. This study aimed to assess, in real …
Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future
A Patel, W Sun - Current treatment options in oncology, 2014 - Springer
Opinion statement Hepatocellular carcinoma (HCC) is one of the most lethal cancers
globally, particularly in certain regions of the world. Although the major risk factors for HCC …
globally, particularly in certain regions of the world. Although the major risk factors for HCC …
Sorafenib in liver cancer—just the beginning
LR Roberts - New England Journal of Medicine, 2008 - Mass Medical Soc
Primary liver cancer is the fifth most common cancer worldwide and the third most common
cause of death from cancer, resulting in more than 600,000 deaths per year. The major risk …
cause of death from cancer, resulting in more than 600,000 deaths per year. The major risk …
[HTML][HTML] Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort …
M Nakano, M Tanaka, R Kuromatsu, H Nagamatsu… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced
hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC …
hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC …